1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Nonalcoholic	_	_	JJ	_	_	_	_	_
2	fatty	_	_	NN	_	_	_	_	_
3	liver	_	_	NN	_	_	_	_	_
4	disease	_	_	NN	_	_	_	_	_
5	(	_	_	-LRB-	_	_	_	_	_
6	NAFLD	_	_	NN	_	_	_	_	_
7	)	_	_	-RRB-	_	_	_	_	_
8	represents	_	_	VBZ	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	leading	_	_	VBG	_	_	_	_	_
11	cause	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	progressive	_	_	JJ	_	_	_	_	_
14	liver	_	_	NN	_	_	_	_	_
15	disorders	_	_	NNS	_	_	_	_	_
16	worldwide	_	_	RB	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	affecting	_	_	VBG	_	_	_	_	_
19	between	_	_	IN	_	_	_	_	_
20	20	_	_	CD	_	_	_	_	_
21	%	_	_	NN	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	40	_	_	CD	_	_	_	_	_
24	%	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	adult	_	_	JJ	_	_	_	_	_
28	population	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	NAFLD	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	defined	_	_	VBN	_	_	_	_	_
4	by	_	_	IN	_	_	_	_	_
5	increased	_	_	VBN	_	_	_	_	_
6	hepatic	_	_	JJ	_	_	_	_	_
7	fat	_	_	NN	_	_	_	_	_
8	accumulation	_	_	NN	_	_	_	_	_
9	not	_	_	RB	_	_	_	_	_
10	explained	_	_	VBN	_	_	_	_	_
11	by	_	_	IN	_	_	_	_	_
12	alcohol	_	_	NN	_	_	_	_	_
13	abuse	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	it	_	_	PRP	_	_	_	_	_
17	encompasses	_	_	VBZ	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	wide	_	_	JJ	_	_	_	_	_
20	spectrum	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	liver	_	_	NN	_	_	_	_	_
23	injuries	_	_	NNS	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	ranging	_	_	VBG	_	_	_	_	_
26	from	_	_	IN	_	_	_	_	_
27	simple	_	_	JJ	_	_	_	_	_
28	steatosis	_	_	NN	_	_	_	_	_
29	(	_	_	-LRB-	_	_	_	_	_
30	>5	_	_	CD	_	_	_	_	_
31	%	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	liver	_	_	NN	_	_	_	_	_
34	weight	_	_	NN	_	_	_	_	_
35	)	_	_	-RRB-	_	_	_	_	_
36	to	_	_	TO	_	_	_	_	_
37	its	_	_	PRP$	_	_	_	_	_
38	inflammatory	_	_	JJ	_	_	_	_	_
39	form	_	_	NN	_	_	_	_	_
40	nonalcoholic	_	_	JJ	_	_	_	_	_
41	steatohepatitis	_	_	NN	_	_	_	_	_
42	(	_	_	-LRB-	_	_	_	_	_
43	NASH	_	_	NNP	_	_	_	_	_
44	)	_	_	-RRB-	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	NASH	_	_	NNP	_	_	_	_	_
2	may	_	_	MD	_	_	_	_	_
3	be	_	_	VB	_	_	_	_	_
4	complicated	_	_	VBN	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	presence	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	fibrosis	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	eventually	_	_	RB	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	it	_	_	PRP	_	_	_	_	_
15	may	_	_	MD	_	_	_	_	_
16	progress	_	_	VB	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	cirrhosis	_	_	NN	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	hepatocellular	_	_	JJ	_	_	_	_	_
21	carcinoma	_	_	NN	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	HCC	_	_	NNP	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	NAFLD	_	_	NNP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	strong	_	_	JJ	_	_	_	_	_
5	inherited	_	_	VBN	_	_	_	_	_
6	component	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	variants	_	_	NNS	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	proteins	_	_	NNS	_	_	_	_	_
12	regulating	_	_	VBG	_	_	_	_	_
13	hepatocellular	_	_	JJ	_	_	_	_	_
14	lipid	_	_	NN	_	_	_	_	_
15	handling	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	including	_	_	VBG	_	_	_	_	_
18	patatin-like	_	_	JJ	_	_	_	_	_
19	phospholipase	_	_	NN	_	_	_	_	_
20	domain-containing	_	_	NN	_	_	_	_	_
21	3	_	_	CD	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	PNPLA3	_	_	NN	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	transmembrane	_	_	NN	_	_	_	_	_
27	6	_	_	CD	_	_	_	_	_
28	superfamily	_	_	NN	_	_	_	_	_
29	member	_	_	NN	_	_	_	_	_
30	2	_	_	CD	_	_	_	_	_
31	(	_	_	-LRB-	_	_	_	_	_
32	TM6SF2	_	_	NN	_	_	_	_	_
33	)	_	_	-RRB-	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	membrane	_	_	NN	_	_	_	_	_
36	bound	_	_	VBN	_	_	_	_	_
37	O-acyltransferase	_	_	NNP	_	_	_	_	_
38	domain-containing	_	_	NN	_	_	_	_	_
39	7	_	_	CD	_	_	_	_	_
40	(	_	_	-LRB-	_	_	_	_	_
41	MBOAT7	_	_	NN	_	_	_	_	_
42	)	_	_	-RRB-	_	_	_	_	_
43	,	_	_	,	_	_	_	_	_
44	predispose	_	_	VB	_	_	_	_	_
45	to	_	_	TO	_	_	_	_	_
46	the	_	_	DT	_	_	_	_	_
47	disease	_	_	NN	_	_	_	_	_
48	development	_	_	NN	_	_	_	_	_
49	and	_	_	CC	_	_	_	_	_
50	progression	_	_	NN	_	_	_	_	_
51	to	_	_	TO	_	_	_	_	_
52	NASH	_	_	NNP	_	_	_	_	_
53	and	_	_	CC	_	_	_	_	_
54	fibrosis	_	_	NN	_	_	_	_	_
55	.	_	_	.	_	_	_	_	_


1	Dietary	_	_	JJ	_	_	_	_	_
2	habits	_	_	NNS	_	_	_	_	_
3	such	_	_	JJ	_	_	_	_	_
4	as	_	_	IN	_	_	_	_	_
5	excessive	_	_	JJ	_	_	_	_	_
6	caloric	_	_	NN	_	_	_	_	_
7	intake	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	fructose	_	_	NN	_	_	_	_	_
10	consumption	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	physical	_	_	JJ	_	_	_	_	_
14	inactivity	_	_	NN	_	_	_	_	_
15	represent	_	_	VBP	_	_	_	_	_
16	other	_	_	JJ	_	_	_	_	_
17	risk	_	_	NN	_	_	_	_	_
18	factors	_	_	NNS	_	_	_	_	_
19	for	_	_	IN	_	_	_	_	_
20	NAFLD	_	_	NN	_	_	_	_	_
21	development	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	its	_	_	PRP$	_	_	_	_	_
5	pathogenesis	_	_	NN	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	closely	_	_	RB	_	_	_	_	_
8	intertwined	_	_	VBN	_	_	_	_	_
9	with	_	_	IN	_	_	_	_	_
10	excessive	_	_	JJ	_	_	_	_	_
11	adiposity	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	insulin	_	_	NN	_	_	_	_	_
14	resistance	_	_	NN	_	_	_	_	_
15	(	_	_	-LRB-	_	_	_	_	_
16	IR	_	_	NN	_	_	_	_	_
17	)	_	_	-RRB-	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	metabolic	_	_	JJ	_	_	_	_	_
21	syndrome	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	IR	_	_	NN	_	_	_	_	_
2	even	_	_	RB	_	_	_	_	_
3	correlates	_	_	VBZ	_	_	_	_	_
4	with	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	severity	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	liver	_	_	NN	_	_	_	_	_
9	fibrosis	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	main	_	_	JJ	_	_	_	_	_
13	determinant	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	NAFLD	_	_	NN	_	_	_	_	_
16	prognosis	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Indeed	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	fibrosis	_	_	NN	_	_	_	_	_
4	has	_	_	VBZ	_	_	_	_	_
5	been	_	_	VBN	_	_	_	_	_
6	observed	_	_	VBN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	diabetic	_	_	JJ	_	_	_	_	_
9	patients	_	_	NNS	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	NAFLD	_	_	NNP	_	_	_	_	_
12	even	_	_	RB	_	_	_	_	_
13	independently	_	_	RB	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	NASH	_	_	NNP	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	genetic	_	_	JJ	_	_	_	_	_
19	variants	_	_	NNS	_	_	_	_	_
20	that	_	_	WDT	_	_	_	_	_
21	impair	_	_	VBP	_	_	_	_	_
22	insulin	_	_	NN	_	_	_	_	_
23	receptor	_	_	NN	_	_	_	_	_
24	(	_	_	-LRB-	_	_	_	_	_
25	InsR	_	_	NN	_	_	_	_	_
26	)	_	_	-RRB-	_	_	_	_	_
27	signaling	_	_	VBG	_	_	_	_	_
28	favor	_	_	NN	_	_	_	_	_
29	fibrosis	_	_	NN	_	_	_	_	_
30	development	_	_	NN	_	_	_	_	_
31	in	_	_	IN	_	_	_	_	_
32	NAFLD	_	_	NN	_	_	_	_	_
33	patients	_	_	NNS	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	mechanism	_	_	NN	_	_	_	_	_
3	whereby	_	_	IN	_	_	_	_	_
4	IR	_	_	NN	_	_	_	_	_
5	aggravates	_	_	VBZ	_	_	_	_	_
6	fibrosis	_	_	NN	_	_	_	_	_
7	may	_	_	MD	_	_	_	_	_
8	be	_	_	VB	_	_	_	_	_
9	related	_	_	VBN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	reduced	_	_	VBN	_	_	_	_	_
12	extracellular	_	_	JJ	_	_	_	_	_
13	matrix	_	_	NN	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	ECM	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	degradation	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	induction	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	proteins	_	_	NNS	_	_	_	_	_
24	involved	_	_	VBN	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	collagen	_	_	NN	_	_	_	_	_
27	crosslinking	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	new	_	_	JJ	_	_	_	_	_
3	perspective	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	NAFLD	_	_	NN	_	_	_	_	_
6	pathogenesis	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	management	_	_	NN	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	provided	_	_	VBN	_	_	_	_	_
11	by	_	_	IN	_	_	_	_	_
12	epigenetics	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	which	_	_	WDT	_	_	_	_	_
15	modulate	_	_	VBP	_	_	_	_	_
16	transcriptome	_	_	NN	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	response	_	_	NN	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	environmental	_	_	JJ	_	_	_	_	_
21	cues	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	particular	_	_	JJ	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	microRNAs	_	_	NNS	_	_	_	_	_
5	(	_	_	-LRB-	_	_	_	_	_
6	miRNAs	_	_	NNS	_	_	_	_	_
7	)	_	_	-RRB-	_	_	_	_	_
8	are	_	_	VBP	_	_	_	_	_
9	short	_	_	JJ	_	_	_	_	_
10	non-protein	_	_	JJ	_	_	_	_	_
11	coding	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	single-strand	_	_	JJ	_	_	_	_	_
14	RNAs	_	_	NNS	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	19	_	_	CD	_	_	_	_	_
17	–	_	_	TO	_	_	_	_	_
18	22	_	_	CD	_	_	_	_	_
19	nucleotides	_	_	NNS	_	_	_	_	_
20	that	_	_	WDT	_	_	_	_	_
21	regulate	_	_	VBP	_	_	_	_	_
22	gene	_	_	NN	_	_	_	_	_
23	expression	_	_	NN	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	cell-to-cell	_	_	NN	_	_	_	_	_
26	communication	_	_	NN	_	_	_	_	_
27	as	_	_	IN	_	_	_	_	_
28	it	_	_	PRP	_	_	_	_	_
29	occurs	_	_	VBZ	_	_	_	_	_
30	between	_	_	IN	_	_	_	_	_
31	hepatocytes	_	_	NNS	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	hepatic	_	_	JJ	_	_	_	_	_
34	stellate	_	_	NN	_	_	_	_	_
35	cells	_	_	NNS	_	_	_	_	_
36	(	_	_	-LRB-	_	_	_	_	_
37	HSCs	_	_	NNS	_	_	_	_	_
38	)	_	_	-RRB-	_	_	_	_	_
39	during	_	_	IN	_	_	_	_	_
40	fibrogenesis	_	_	NN	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	Alteration	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	miRNA	_	_	NN	_	_	_	_	_
4	expression	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	response	_	_	NN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	genetic/epigenetic	_	_	JJ	_	_	_	_	_
9	factors	_	_	NNS	_	_	_	_	_
10	or	_	_	CC	_	_	_	_	_
11	environmental	_	_	JJ	_	_	_	_	_
12	conditions	_	_	NNS	_	_	_	_	_
13	may	_	_	MD	_	_	_	_	_
14	contribute	_	_	VB	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	steatosis	_	_	NN	_	_	_	_	_
17	onset	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	NAFLD	_	_	NN	_	_	_	_	_
20	progression	_	_	NN	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	fibrosis	_	_	NN	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	cancer	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	mirroring	_	_	VBG	_	_	_	_	_
27	the	_	_	DT	_	_	_	_	_
28	histological	_	_	JJ	_	_	_	_	_
29	features	_	_	NNS	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	molecular	_	_	JJ	_	_	_	_	_
33	events	_	_	NNS	_	_	_	_	_
34	occurring	_	_	VBG	_	_	_	_	_
35	in	_	_	IN	_	_	_	_	_
36	NAFLD	_	_	NNP	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	they	_	_	PRP	_	_	_	_	_
4	could	_	_	MD	_	_	_	_	_
5	be	_	_	VB	_	_	_	_	_
6	exploited	_	_	VBN	_	_	_	_	_
7	as	_	_	IN	_	_	_	_	_
8	attractive	_	_	JJ	_	_	_	_	_
9	candidate	_	_	NN	_	_	_	_	_
10	biomarkers	_	_	NNS	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	an	_	_	DT	_	_	_	_	_
13	accurate	_	_	JJ	_	_	_	_	_
14	profiling	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	different	_	_	JJ	_	_	_	_	_
18	stages	_	_	NNS	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	liver	_	_	NN	_	_	_	_	_
21	injury	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	enabling	_	_	VBG	_	_	_	_	_
24	early	_	_	JJ	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	non-invasive	_	_	JJ	_	_	_	_	_
27	diagnosis	_	_	NN	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	clinical	_	_	JJ	_	_	_	_	_
31	monitoring	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	disease	_	_	NN	_	_	_	_	_
35	progression	_	_	NN	_	_	_	_	_
36	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	we	_	_	PRP	_	_	_	_	_
4	aimed	_	_	VBD	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	explore	_	_	VB	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	mechanisms	_	_	NNS	_	_	_	_	_
9	through	_	_	IN	_	_	_	_	_
10	which	_	_	WDT	_	_	_	_	_
11	epigenetics	_	_	NNS	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	environmental	_	_	JJ	_	_	_	_	_
14	factors	_	_	NNS	_	_	_	_	_
15	interact	_	_	VBP	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	promote	_	_	VB	_	_	_	_	_
18	progressive	_	_	JJ	_	_	_	_	_
19	NAFLD	_	_	NN	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	context	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	IR	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	purpose	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	we	_	_	PRP	_	_	_	_	_
6	first	_	_	RB	_	_	_	_	_
7	assessed	_	_	VBD	_	_	_	_	_
8	which	_	_	WDT	_	_	_	_	_
9	miRNAs	_	_	NNS	_	_	_	_	_
10	were	_	_	VBD	_	_	_	_	_
11	deregulated	_	_	VBN	_	_	_	_	_
12	by	_	_	IN	_	_	_	_	_
13	IR	_	_	NNP	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	HSCs	_	_	NNPS	_	_	_	_	_
16	whose	_	_	WP$	_	_	_	_	_
17	activation	_	_	NN	_	_	_	_	_
18	represents	_	_	VBZ	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	hallmark	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	liver	_	_	NN	_	_	_	_	_
23	fibrosis	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Secondly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	we	_	_	PRP	_	_	_	_	_
4	evaluated	_	_	VBD	_	_	_	_	_
5	whether	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	miRNAs	_	_	NNS	_	_	_	_	_
8	differentially	_	_	RB	_	_	_	_	_
9	expressed	_	_	VBD	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	insulin	_	_	NN	_	_	_	_	_
12	resistant	_	_	JJ	_	_	_	_	_
13	HSCs	_	_	NNS	_	_	_	_	_
14	could	_	_	MD	_	_	_	_	_
15	impact	_	_	VB	_	_	_	_	_
16	on	_	_	IN	_	_	_	_	_
17	NAFLD-related	_	_	JJ	_	_	_	_	_
18	fibrosis	_	_	NN	_	_	_	_	_
19	by	_	_	IN	_	_	_	_	_
20	using	_	_	VBG	_	_	_	_	_
21	an	_	_	DT	_	_	_	_	_
22	experimental	_	_	JJ	_	_	_	_	_
23	model	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	IR-NASH	_	_	NNP	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	investigate	_	_	VB	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	independent	_	_	JJ	_	_	_	_	_
7	contribution	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	IR	_	_	NNP	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	NASH	_	_	NNP	_	_	_	_	_
12	that	_	_	WDT	_	_	_	_	_
13	is	_	_	VBZ	_	_	_	_	_
14	usually	_	_	RB	_	_	_	_	_
15	intertwined	_	_	VBN	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	patients	_	_	NNS	_	_	_	_	_
18	on	_	_	IN	_	_	_	_	_
19	miRNAs	_	_	NNS	_	_	_	_	_
20	expression	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	IR	_	_	NNP	_	_	_	_	_
23	was	_	_	VBD	_	_	_	_	_
24	induced	_	_	VBN	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	mice	_	_	NNS	_	_	_	_	_
27	by	_	_	IN	_	_	_	_	_
28	haploinsufficiency	_	_	NN	_	_	_	_	_
29	for	_	_	IN	_	_	_	_	_
30	InsR	_	_	NNP	_	_	_	_	_
31	(	_	_	-LRB-	_	_	_	_	_
32	InsR+/−	_	_	NNP	_	_	_	_	_
33	)	_	_	-RRB-	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	which	_	_	WDT	_	_	_	_	_
36	determines	_	_	VBZ	_	_	_	_	_
37	an	_	_	DT	_	_	_	_	_
38	impairment	_	_	NN	_	_	_	_	_
39	of	_	_	IN	_	_	_	_	_
40	hepatic	_	_	JJ	_	_	_	_	_
41	insulin	_	_	NN	_	_	_	_	_
42	signaling	_	_	VBG	_	_	_	_	_
43	recapitulating	_	_	VBG	_	_	_	_	_
44	that	_	_	WDT	_	_	_	_	_
45	has	_	_	VBZ	_	_	_	_	_
46	been	_	_	VBN	_	_	_	_	_
47	observed	_	_	VBN	_	_	_	_	_
48	in	_	_	IN	_	_	_	_	_
49	NAFLD	_	_	NNP	_	_	_	_	_
50	patients	_	_	NNS	_	_	_	_	_
51	.	_	_	.	_	_	_	_	_


1	Conversely	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	model	_	_	VB	_	_	_	_	_
5	fibrogenic	_	_	JJ	_	_	_	_	_
6	NASH	_	_	NNP	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	we	_	_	PRP	_	_	_	_	_
9	exploited	_	_	VBD	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	methionine	_	_	NN	_	_	_	_	_
12	choline	_	_	NN	_	_	_	_	_
13	deficient	_	_	JJ	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	MCD	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	diet	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	which	_	_	WDT	_	_	_	_	_
20	impairs	_	_	VBZ	_	_	_	_	_
21	phospholipid	_	_	NN	_	_	_	_	_
22	metabolism	_	_	NN	_	_	_	_	_
23	without	_	_	IN	_	_	_	_	_
24	altering	_	_	VBG	_	_	_	_	_
25	IR	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Finally	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	we	_	_	PRP	_	_	_	_	_
4	tested	_	_	VBD	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	expression	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	candidate	_	_	NN	_	_	_	_	_
10	miRNAs	_	_	NNS	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	immortalized	_	_	VBN	_	_	_	_	_
13	human	_	_	JJ	_	_	_	_	_
14	hepatoma	_	_	NN	_	_	_	_	_
15	cells	_	_	NNS	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	HepG2	_	_	NNP	_	_	_	_	_
18	)	_	_	-RRB-	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	HSCs	_	_	NNP	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	LX-2	_	_	NN	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	presence	_	_	NN	_	_	_	_	_
28	or	_	_	CC	_	_	_	_	_
29	absence	_	_	NN	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	miRNA	_	_	NN	_	_	_	_	_
32	mimics	_	_	NNS	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	Here	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	we	_	_	PRP	_	_	_	_	_
4	showed	_	_	VBD	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	miR-101-3p	_	_	CD	_	_	_	_	_
7	was	_	_	VBD	_	_	_	_	_
8	downregulated	_	_	VBN	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	InsR+/−	_	_	NNP	_	_	_	_	_
11	HSCs	_	_	NNPS	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	hepatocytes	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	its	_	_	PRP$	_	_	_	_	_
16	expression	_	_	NN	_	_	_	_	_
17	was	_	_	VBD	_	_	_	_	_
18	reduced	_	_	VBN	_	_	_	_	_
19	even	_	_	RB	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	total	_	_	JJ	_	_	_	_	_
22	livers	_	_	NNS	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	insulin	_	_	NN	_	_	_	_	_
25	resistant	_	_	JJ	_	_	_	_	_
26	mice	_	_	NNS	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	it	_	_	PRP	_	_	_	_	_
30	was	_	_	VBD	_	_	_	_	_
31	associated	_	_	VBN	_	_	_	_	_
32	with	_	_	IN	_	_	_	_	_
33	all	_	_	DT	_	_	_	_	_
34	stages	_	_	NNS	_	_	_	_	_
35	of	_	_	IN	_	_	_	_	_
36	liver	_	_	NN	_	_	_	_	_
37	disease	_	_	NN	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	Consistently	_	_	RB	_	_	_	_	_
2	with	_	_	IN	_	_	_	_	_
3	these	_	_	DT	_	_	_	_	_
4	results	_	_	NNS	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	target	_	_	NN	_	_	_	_	_
7	prediction	_	_	NN	_	_	_	_	_
8	analysis	_	_	NN	_	_	_	_	_
9	revealed	_	_	VBD	_	_	_	_	_
10	that	_	_	IN	_	_	_	_	_
11	miR-101-3p	_	_	NN	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	involved	_	_	VBN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	insulin	_	_	NN	_	_	_	_	_
16	signaling	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	lipid	_	_	NN	_	_	_	_	_
19	metabolism	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	cell	_	_	NN	_	_	_	_	_
22	proliferation	_	_	NN	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	fibrogenesis	_	_	NN	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	cancer	_	_	NN	_	_	_	_	_
28	susceptibility	_	_	NN	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	possibly	_	_	RB	_	_	_	_	_
31	representing	_	_	VBG	_	_	_	_	_
32	a	_	_	DT	_	_	_	_	_
33	molecular	_	_	JJ	_	_	_	_	_
34	signature	_	_	NN	_	_	_	_	_
35	in	_	_	IN	_	_	_	_	_
36	NAFLD	_	_	NN	_	_	_	_	_
37	during	_	_	IN	_	_	_	_	_
38	IR	_	_	NNP	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	miR-101-3p	_	_	NN	_	_	_	_	_
4	overexpression	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	HepG2	_	_	NNP	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	LX-2	_	_	NNP	_	_	_	_	_
9	reduced	_	_	VBD	_	_	_	_	_
10	proliferation	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	migration	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	invasiveness	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	regulating	_	_	VBG	_	_	_	_	_
18	pro-fibrotic	_	_	JJ	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	pro-carcinogenic	_	_	JJ	_	_	_	_	_
21	markers	_	_	NNS	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_

